The US drug regulator on Thursday said only people with mild dementia should receive the first new Alzheimer's medicine in decades, after facing intense backlash from many in the medical community over its authorization

The US drug regulator on Thursday said only people with mild dementia should receive the first new Alzheimer's medicine in decades, after facing intense backlash from many in the medical community over its authorization: https://ift.tt/2TJw3KI Read more... https://ift.tt/3yDa0nv